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Clinical question: What is the best treatment for artemisinin-resistant malaria?
Results: There is still no better treatment than the presently used artemisinin-based combination 
therapies. A new antimalarial drug for this problem needs to be found.
Implementation: Pitfalls to avoid when treating drug-resistant malaria:
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Drug-resistant malaria
Definition: A “drug-resistant malaria” is a malarial infection that is not responding to 
the standard basic antimalarial treatment. Artemisinin is a drug used to treat multi-drug 
resistant strains of falciparum malaria. The World Health Organization has recom-
mended that a switch to artemisinin combination therapies be made in all countries 
where the malaria parasite has developed resistance to chloroquine. Their site of action 
within the parasite remains controversial. At the chemical level, one theory states that 
when the parasite that causes malaria infects a red blood cell, it consumes hemoglobin 
within its digestive vacuole, liberating free heme, an iron–porphyrin complex. The 
iron reduces the peroxide bond in artemisinin, generating high-valency iron-oxo 
species and  resulting in a cascade of reactions that produce reactive oxygen radicals 
that damage the parasite, leading to its death. Recently, emergence of new artemisinin 
drug-resistant malaria has been reported. This problem for falciparum malaria, of which 
artemisinin-based combination therapies are the recommended standard treatments, 
is specifically focused on herein.
Etiology: Resistant strain of malarial parasite.
Incidence: The incidence of drug-resistant malaria is different in different settings. 
The highest incidence is reported in Indochina (Thai–Cambodia border and Thai-
Myanmar border).1
Economics: No published study has addressed the economic issues of drug-
resistant malaria. However, Foster et al reports that about US$1800 million is spent 
annually.2
Level of evidence: Systematic reviews, meta-analyses, randomized controlled trials 
(RCTs).
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Search sources: PubMed, Cochrane Library, NHS Evi-
dence, DARE, clinical evidence.
Outcomes: From the patient perspective the main out-
comes are:
1.  Success in antimalarial drug treatment.
2.  Avoidance of complications and death.
Consumer summary: The standard classical antimalarial 
drugs are not fully effective against emerging strains of 
drug-resistant malaria. The period of taking drugs has to 
be extended from that normally given. The control of drug 
use and surveillance of drug-resistant strains are the present 
means to fight this problem. New antimalarial drugs to solve 
the forthcoming problem are required.
The practice
How does artemisinin-resistant malaria 
affect the present standard antimalarial 
treatment?
Systematic reviews: 1
Meta-analyses: 3
RCTs: 1
There is a systematic review on artemisinin-resistant 
falciparum malaria.3 Partial artemisinin resistance is the 
present problem.3 The emerging problem is proposed to 
be due to selection of the resistant phenotype which is the 
result of exposure of the parasite population to artemisinin 
monotherapies in subtherapeutic doses for over 30 years, 
and the availability of substandard artemisinins.3 Focusing 
on the  meta-analyses, for non-artemisinin-resistant cases, 
it is noted that “The addition of 3 days of artesunate to 
standard antimalarial treatments substantially reduces treat-
ment failure, recrudescence, and gametocyte carriage.”4 
Similar notes are reported in the other two meta-analyses.5,6 
However, there is no specific meta-analysis on artemisinin-
resistant falciparum malaria. The randomized trial concluded 
“Resistance is characterized by slow parasite clearance in 
vivo without corresponding reductions on conventional in 
vitro susceptibility testing.”7
Which treatments are best for cases  
of drug-resistant malaria?
Systematic reviews: 0
Meta-analyses: 0
RCTs: 1
There are no systematic reviews or meta-analyses for 
artemisinin-resistant falciparum malaria. The randomized 
trial showed that the present artemisinin-based combination 
therapies are still successful treatments but the clearance of 
malaria took longer than for the non-resistant cases.7
Prolonged drug administration is required and there is 
no report of adverse drug reaction due to this extended drug 
administration.7
Conclusion
There is evidence on emergence of artemisinin-resistant 
malaria from highly endemic areas in Southeast Asia. Longer 
administration of standard artemisinin-based combination 
therapies is required for treatment of drug-resistant malaria. 
If resistance is complete, failure of present artemisinin-based 
combination therapies can be expected, and development of 
a new antimalarial drug for artemisinin-resistant malaria is 
required.
The evidence
Potential pitfalls
Entering the endemic areas without concern for the 
existence of new drug-resistant malaria might lead to a lack 
of prevention. A history of exposure is required for early 
diagnosis and adjustment for the longer artemisinin-based 
combination therapies.
Management
Artemisinin-resistant malaria should not be managed by 
non-specialists. Suspected cases should be referred to 
specialists in infectious diseases or tropical medicine.
Assessment
•	 Traveling or living in the endemic areas (Indochina, 
Southeast Asia) poses a high risk.
•	 If history suggests a possibility of exposure and the diag-
nosis confirms falciparum malaria, refer to a specialist.
•	 If the primary standard treatment does not clear malaria, 
reassessment of patient history is needed and referral to 
a specialist is suggested.
Treatment
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•	 Prolonged artemesin treatment is the present standard 
recommendation and there is no suggested alternative 
treatment.
•	 Long artemisinin-based combination treatment until 
clearance of malaria.
•	 Close monitoring of clinical appearance and parasite 
clearance during treatment.
•	 Reporting to the local disease control authority is 
required.
Indications for specialist referral
•	 A history of visiting endemic areas.
•	 Failure of primary standard artemisinin-based combina-
tion treatments.
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